Cytomegalovirus Infection after CD34 + -Selected Hematopoietic Cell Transplantation-Reference-Cited by-同舟云学术

Cytomegalovirus Infection after CD34 + -Selected Hematopoietic Cell Transplantation

Published:2016-08 Issue:8 Volume:22 Page:1480-1486
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Huang Yao-Ting,Neofytos Dionysios,Foldi Julia,Kim Seong Jin,Maloy Molly,Chung Dick,Castro-Malaspina Hugo,Giralt Sergio A.,Papadopoulos Esperanza,Perales Miguel-Angel,Jakubowski Ann A.,Papanicolaou Genovefa A.

Funder

National Cancer Institute

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference29 articles.

1. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy;Boeckh;Blood,2004

2. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age;Kollman;Blood,2001

3. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection;Nichols;J Infect Dis,2002

4. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis;Ljungman;Blood,2003

5. Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European group for Blood and Marrow Transplantation;Ljungman;Clin Infect Dis,2014

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune reconstitution, vaccine responses, and rituximab use after ex-vivo CD34-selected myeloablative allogenic hematopoietic cell transplantation;Bone Marrow Transplantation;2024-02-13

2. Emergence of human CMV-induced NKG2C+ NK cells is associated with CD8+ T-cell recovery after allogeneic HCT;Blood Advances;2023-09-29

3. Cost Effectiveness of Letermovir for Cytomegalovirus Prophylaxis Compared with Pre-Emptive Therapy in Allogeneic Hematopoietic Stem Cell Transplant Recipients in the United States;PharmacoEconomics - Open;2023-02-25

4. How I Prevent Viral Reactivation in High-risk Patients;Blood;2022-12-09

5. Ex vivo and in vivo T-cell depletion in allogeneic transplantation: towards less or non-cytotoxic conditioning regimens;Expert Review of Clinical Immunology;2022-11-03